ArticleMedical oncology (Northwood, London, England)2026
Engineered mesenchymal stem cell-derived small extracellular vesicles delivering miR-124 suppress colorectal cancer progression through EZH2 downregulation and attenuation of STAT3 signaling.
Article in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) progression is driven by dysregulated molecular pathways and epigenetic alterations, including enhancer of zeste homolog 2 (EZH2)-mediated histone methylation and STAT3 hyperactivation. While microRNA-124 (miR-124) acts as a tumor suppressor by targeting EZH2, its clinical translation is hindered by delivery challenges. Here, we engineered mesenchymal stem cell-derived small extracellular vesicles (MSC-sEVs) to deliver miR-124, exploiting their tumor-homing capacity and biocompatibility to suppress CRC progression. Bioinformatic analysis of clinical datasets revealed miR-124 downregulation in CRC tissues, correlating with advanced stages and poor prognosis. Lentiviral transduction enabled efficient miR-124 packaging into MSC-sEVs, which were internalized by CRC cells, restoring functional miR-124 levels. Mechanistically, miR-124 directly silenced EZH2, thereby suppressing its oncogenic activity. This led to attenuated STAT3 phosphorylation-a dual effect that inhibited proliferation, migration, and epithelial-mesenchymal transition (EMT) in CRC cells. In vitro, MSC-sEV-miR-124 induced apoptosis, sensitized cells to 5-fluorouracil, and reversed chemoresistance via EZH2 downregulation. In vivo, MSC-sEV-miR-124 significantly reduced tumor growth in BALB/c mice, downregulated EZH2/STAT3 signaling, and suppressed Ki-67 and EMT markers in xenografts. This study provides proof-of-concept that engineered MSC-sEVs can serve as a delivery platform for miR-124 in murine CRC models, offering a dual-targeting strategy against EZH2 and STAT3 to disrupt CRC progression. Our findings suggest that EV-based miRNA delivery warrants further investigation as a strategy to modulate the tumor microenvironment, providing a foundation for development aimed at overcoming epigenetic and oncogenic signaling barriers in CRC therapy.
Indexed as
Identifiers
42848258What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.